Navigation Links
Kiadis Pharma Continues to Provide Rhitol to Participating Physicians During Completion of Current Clinical Study
Date:11/19/2007

AMSTERDAM, November 19 /PRNewswire/ -- Kiadis Pharma announced today that it has agreed to provide Rhitol during a limited period of time to requesting physicians participating in the ongoing phase I/II trial. The Rhitol phase I/II trial is closed for enrolment to treat new patients and is expected to complete at the end of this year. Kiadis Pharma anticipates applying for and starting a phase III study in 2008.

Manja Bouman, CEO Kiadis Pharma commented: "We realised that the sites participating in the ongoing phase II trial were left without treatment alternatives following the announcement of the enrolment closure. The interest these physicians show in using our product for new patients is very encouraging and we are very pleased that we can support them by providing Rhitol through special provisions, until the start of the phase III clinical trial."

The physicians interested in enabling new patients to receive treatment with Rhitol will obtain regulatory authorization from the appropriate agency to allow for compassionate use of Rhitol.

Rhitol is under development for patients with severe chronic steroid refractory Graft versus Host Disease (GvHD) who have exhausted other treatment options. Chronic GvHD is a condition that can develop after allogeneic bone marrow transplantation and resembles an autoimmune disease. The immune cells from the donor graft cause GvHD by attacking the patient's tissues and organs. There are two forms of GvHD: acute GvHD appears within 100 days after transplantation and chronic GvHD begins anytime after that period. Immune-suppressant drugs, such as steroids, are generally used to treat chronic GvHD. The disease can become a life-threatening condition when standard treatment cannot control its progression as the patient either does not respond to steroid treatment or develops severe side effects due to their use. Extensive chronic GvHD affects multiple organs and tissues and results in diminished quality of lif
'/>"/>

SOURCE Kiadis Pharma B.V.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Kiadis Pharma Announces ATIR Interim Clinical Results
2. FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation
3. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
4. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
10. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
11. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/20/2014)... company LunaDress has recently announced its 2015 collection ... discounts on all of its special occasion dresses & wedding ... perfect wedding gown. If you have no idea of what ... Many different wedding dress styles and our dress experts are ... the current special offer, up to 80% off," the CEO ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 DePuy ... a metal-on-metal version of the artificial hip system ... state and federal courts, Bernstein Liebhard LLP reports. ... Bergen County Superior Court on December 2nd, counsel ... begin deposition of plaintiffs on November 19, 2014, ...
(Date:12/20/2014)... The print component of Healthy Aging ... of approximately 160,000 copies and an estimated readership of ... vast social media strategy and across a network of ... digital version of the campaign, click here . ... the ladies of CTV’s The Social. Lainey Lui, ...
(Date:12/20/2014)... News) -- The holidays can be anything but joyous ... trees, scented candles and other allergy triggers. "The ... have been packed away in dank basements or dusty ... patients," Dr. Rachna Shah, an affiliate faculty member at ... Loyola news release. Shah, who is also an ...
(Date:12/20/2014)... December 20, 2014 Recently, VogueQueen.com, a ... VogueQueen Big Sale Online for 2015. Great ... All new and old consumers can get a discount, ... at the company’s website before January 30, 2015. , ... dresses and launched a prom dress promotion. Many customers ...
Breaking Medicine News(10 mins):Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:Holiday Trimmings Can Trigger Allergies 2Health News:VogueQueen Big Sale Online For The Coming 2015 2
... Corporation,(Nasdaq: MDTH ) announced that its senior management ... 2008 Health Care Conference,held May 13 - 15 at ... senior management will give its presentation on Tuesday, May,13 ... web cast live over,the Internet via MedCath,s website ( ...
... TORONTO, May 9 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals ... development and,commercialization of cancer therapies, today announced ... Operational Highlights, During the three ... achieved the,following steps in preparation for the ...
... Two Operations Leads to Indictment of 11,Defendants in ... people have been,indicted in the second phase of ... and health care companies that,fraudulently bill the Medicare ... S. Fisher and U.S. Attorney for the Central,District ...
... May 8 HealthSouth,Corporation (NYSE: HLS ) today ... things, elect directors and provide an update on the,company,s ... More than 88.5% of the outstanding shares eligible ... or by proxy and the board,s,nominated slate of directors ...
... PHOENIX, May 8 NutraCea (OTC Bulletin Board:,NTRZ), ... nutrient research and,technology, announced today that it will ... 12 after the market closes., Management will ... Monday, May,12th to review the first quarter financial ...
... 8 Shortly after the gruesome,discovery of aborted babies ... in early March, Citizens for a Pro-Life Society,discovered the ... Advisory Clinic in Livonia, Michigan, owned by Dr. Reginald ... times in which we live that we,must stop and ...
Cached Medicine News:Health News:Bradmer announces 2008 first quarter operational and financial results 2Health News:Bradmer announces 2008 first quarter operational and financial results 3Health News:Bradmer announces 2008 first quarter operational and financial results 4Health News:Bradmer announces 2008 first quarter operational and financial results 5Health News:Bradmer announces 2008 first quarter operational and financial results 6Health News:Bradmer announces 2008 first quarter operational and financial results 7Health News:Bradmer announces 2008 first quarter operational and financial results 8Health News:Strike Force Targets Medicare Fraud By Los Angeles Area Health Care Companies 2Health News:Strike Force Targets Medicare Fraud By Los Angeles Area Health Care Companies 3Health News:Strike Force Targets Medicare Fraud By Los Angeles Area Health Care Companies 4Health News:Strike Force Targets Medicare Fraud By Los Angeles Area Health Care Companies 5Health News:HealthSouth Board Re-Elected at Annual Shareholder Meeting 2Health News:NutraCea to Host First Quarter 2008 Conference Call on May 12. 2Health News:ALL: More Dead Babies Found in Michigan Dumpsters 2
(Date:12/19/2014)... the Friday, December 19 edition of USA ... (HIT) features Konica Minolta, the company announced today. The supplement will ... healthcare organizations. In addition to the print section ... New York , Chicago , ... Minneapolis and San Francisco , ...
(Date:12/19/2014)... TODAY, AEGATE, the leader in medicine verification ... of Peter Fox as Chief Technology Officer ... Officer. Peter has served as Development Director ... Oracle in 2011. Prior to Datanomic, Peter ... and subsequently Convergys, a world renowned billing system for ...
(Date:12/19/2014)... 2014  Newport Corporation (NASDAQ: NEWP ... joined the company,s Board of Directors.  Dr. Kadia ... director of Evans Analytical Group, a leading global ... services to companies in a wide range of ... Analytical Group, Dr. Kadia spent nine years with ...
Breaking Medicine Technology:USA Today Supplement Featuring Konica Minolta Focuses on Impact of Healthcare IT 2Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2
... term follow up results from chronically infected Hepatitis C,patients strongly confirm and exceed ... to show a statistically significant and long-term ... the way and strongly support move into a second generation, vaccine formulated ... ...
... the risk of,stroke by 34% in patient with atrial fibrillation ... adequately treated by ... of a,post-hoc analysis of the data from the ATHENA study ... European Society of Cardiology,congress 2008, in Munich, Germany. Previous results ...
Cached Medicine Technology:Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: